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Background. Parainfluenza virus (PIV) is a significant cause of morbidity and 
mortality in children and the immunocompromised adult population, but its clin-
ical manifestation, impact, and outcomes in hospitalized adults is not well studied.
Methods. Retrospectively, adults ≥ 18  years old admitted to Northwestern 
Memorial Hospital (Chicago, IL) or Prentice Women’s Hospital (Chicago, IL) between 
August 1, 2009 and July 31, 2016 with a positive molecular test for PIV were included in 
the study. Epidemiologic, clinical, and outcomes data were retrospectively collected from 
the enterprise data warehouse and patient electronic health records after IRB approval.
Results. 550 adults with a positive molecular test for PIV were identified (see 
Table 1). Differences in seasonality, presentation (significant for cough, sputum), and 
outcomes of PIV serotype (-1, -2, and -3) were identified (see Table 2, Figure 1). At 
presentation, most patients had cough (88%), productive sputum (55%), fever (63%), 
and dyspnea (49%). 348 (63.3%) of patients were administered antibiotics with no con-
firmed bacterial infection. Patients given antibiotics had a longer length of hospital stay 
(6.9 d vs 3.2 d (P < 0.0001)). Presence of bacterial co-infections (P = 0.02), BMI (lower 
BMI associated with death, P = 0.01), dyspnea (P = 0.04) and various laboratory studies 
(ANC, ALC, Hematocrit, BUN, and AST) were associated with significant differences 
in outcome (see Table 3).
Conclusion. PIV infection results in significant morbidity in hospitalized adults. 
With improved diagnostic testing availability and knowledge of clinical manifestation, 
identification of PIV infections will improve. Future efforts should be directed at devel-
oping novel preventative and therapeutic approaches to PIV infection. 
Figure 1. Monthly Prevalence of PIV by Serotype Over 7 Year Period.
Table 2. Comparing PIV Serotypes in Hospitalized Adults
Characteristics PIV-1 PIV-2 PIV-3 p value
Prevalence, n (%) 122 (22.2) 96 (17.5) 332 (60.4) -
Age, years 59.7 57.2 61.5 0.08
Presenting Symptoms, %
 Cough 87.6 74.0 93.1 < 0.0001
 Sputum 60.3 41.7 57.2 0.011
 Fever 70.2 60.4 61.3 0.18
 Dyspnea 45.5 47.9 51.1 0.55
 Rhinorrhea 20.6 16.7 32.6 0.001
Clinical Course
 Hospital stay, days 8.88 7.9 7.2 0.37
 Received Abx, % 81.1 71.9 81.3 0.11
 ICU admissions, n (%) 26 (21.3) 26 (27.1) 78 (23.4) 0.58
 ICU stay, days 10.1 9.2 5.9 0.131
Disclosures. M. G. Ison, Beckman Coulter: Grant Investigator, Research grant; 
Chimerix: Grant Investigator, Research  grant; Gilead: Grant Investigator, Research 
grant
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Background. The IDSA Community-Acquired Pneumonia (CAP) Guideline 
recommends ceftriaxone in combination with doxycycline as an alternative to com-
bination therapy with ceftriaxone and azithromycin for non-intensive care unit (ICU) 
patients hospitalized with CAP. This is an attractive alternative regimen due to recent 
concerns of increased cardiovascular risk associated with azithromycin. The objective 
of this study was to compare the clinical outcomes of azithromycin and doxycycline 
each in combination with ceftriaxone for non-ICU Veterans hospitalized with CAP.
Methods. This retrospective cohort study included Veterans with pneumonia 
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who received ceftriaxone plus either azithromycin or doxycycline within 48 hours of 
admission. Demographics, modified CURB-65, Charleston Comorbidity Index (CCI), 
antimicrobials received, and microbiology data were obtained. A composite outcome 
was used to assess clinical failure and included either broadened antimicrobial cover-
age during index hospitalization, mortality, readmission, or emergency department 
visit within 30 days. Univariate and multivariate logistic regression were performed to 
identify risk factors associated with clinical outcomes.
Results. 3788 patients met inclusion criteria: 3711 in the azithromycin group and 
77 in the doxycycline group. These were well-matched according to CAP severity and 
comorbidities. There was no statistical difference in the composite outcome between the 
azithromycin and doxycycline groups (44.3% vs 51.9%, P = 0.18). Multivariate analysis 
identified positive blood culture (OR 5.81, 95% CI 2.69–12.55), CURB-65 [2 vs 0] (OR 
1.24, 95% CI 1.05–1.47), CURB-65 [≥3 vs 0] (OR 2.4, 95% CI 1.22–4.71) and CCI (OR 
1.1, 95% CI 1.06–1.14) as risk factors for the composite outcome. Receipt of doxycycline 
was not associated with components of the composite outcome in secondary analyses.
Conclusion. Doxycycline was not associated with a statistical difference in the 
composite outcome for non-ICU Veterans hospitalized for CAP compared with azith-
romycin. These data offer support for the inclusion of doxycycline as an alternative 
regimen in current IDSA recommendations.
Disclosures. All authors: No reported disclosures. 
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Background. The beginning of the 2014–2015 respiratory season in the United 
States was marked by reports of a re-emergent subtype of enterovirus (EV-D68). 
Documented EV-D68 was associated with severe asthma exacerbations and neuro-
logic effects; however rapid assays in clinical use detect rhinovirus/enterovirus more 
broadly. The objective of our study was to determine the prevalence of EV-D68 as well 
as non-EV-D68 rhinovirus and enterovirus subtypes during the epidemic period.
Methods. Residual nasal swab specimens were obtained from the University of 
Michigan clinical microbiology laboratory for children and adults presenting for care 
due to acute respiratory symptoms from September to November 2014. Specimens 
were restricted to those testing positive for “Rhinovirus / Enterovirus” (RV/EV+) by 
the FilmArray Respiratory Virus Panel (Biofire Diagnostics). Specimens were tested 
to identify EV-D68 by real-time RT-PCR and serotype was determined for non-
EV-D68 specimens through amplification and Sanger sequencing of a segment of the 
5’ non-coding region using previously published assays.
Results. A total of 159 patients with acute respiratory illness were included with 
RV/EV+ nasal swab specimens collected from September to November 2014. Sixty-
four percent (n = 101)  of patients were children. Unexpectedly, only 20 RV/EV+ 
specimens were the EV-D68 subtype, with 13 detections in children (13%) and 7 in 
adults (12%). Rhinovirus A was the most frequently identified group among adults (n 
= 23; 40%); rhinovirus C was the most frequently identified in children (n = 43; 43%) 
(Figure). In the children, 13 different serotypes of rhinovirus-C and 21 different sero-
types of group A were identified.
Conclusion. We found rhinovirus C to be a major contributor to rhinovirus-as-
sociated hospitalizations in children during the time of the EV-D68 epidemic period 
in the United States. These data demonstrate that local determinations of the burden 
of EV-D68 require the use of subtype-specific assays. In addition, our results add to 
the growing evidence of the important role of rhinovirus group C in severe acute res-
piratory infections.
Disclosures. E. T.  Martin, Pfizer: Scientific Advisor, Research  grant; Merck: 
Scientific Advisor, Research grant; Multiparty Group For Advice on Science: Scientific 
Advisor, Research grant 
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Background. The current ATS/IDSA pneumonia guidelines lacks a concise def-
inition of immunosuppression, which causes significant heterogeneity in antibiotic use 
for patients with MMI. Furthermore, the impact of mild-moderate immune suppres-
sion on pneumonia severity, incidence of multi-drug resistant (MDR) pathogens, dis-
ease course and clinical outcomes has not been well described.
Methods. This multicenter observational cohort study included non-ICU 
patients diagnosed with pneumonia within 48 hours of admission from 10 hospitals 
between November 2015 and November 2016. MMI patients were defined as asplenic; 
HIV with CD4 count ≥200; non-neutropenic leukemic or solid malignancy receiving 
treatment in the previous 30 days; kidney transplant >1 year ago without rejection; 
receiving ≥15  mg/day prednisone for ≥30  days, TNF-alpha inhibitor, azathioprine 
or methotrexate use. All cause 30-day mortality, pneumonia severity, hospital length 
of stay (LOS), pneumonia readmissions, MDR pathogen (resistant to levofloxacin or 
ceftriaxone), and time to clinical stability were compared between MMI and immuno-
competent patients.
Results. A total of 2,505 patients with pneumonia were included and 274 (11%) 
were classified as MMI. Similar rates of respiratory and blood cultures were obtained 
between MMI and immunocompetent groups (88.7% vs. 85.1%, P > 0.05), but the 
MMI group demonstrated a higher rate of culture positivity (19% vs. 15.5%, P = 0.013). 
There was no difference in culture positivity with traditional CAP pathogens between 
groups (5.5% vs. 5.2%, P > 0.05), but MMI patients had higher incidence of MDR 
pathogens (72.4% vs. 39.5%, P = 0.002). MMI patients presented with more severe 
disease (PSI of 115.6 vs. 87.2, P < 0.001), had higher mortality rates (7.7% vs. 2.1%, P < 
0.001), and longer LOS (5.4 vs. 4.7 days, P < 0.001). However, time to clinical stability 
(2.6 vs. 2.64 days, P = 0.79) and recurrent pneumonia rates (34.8 vs. 33.8%, P = 0.89) 
were similar.
Conclusion. MMI patients with pneumonia have a higher incidence of MDR 
pathogens. and culture positivity. MMI patients also have a higher mortality rate and 
longer LOS. Antibiotic regimens which extend coverage beyond traditional CAP path-
ogens may be needed in MMI patients, but broader coverage could be more targeted if 
risk factors for MDR pathogens in this population were identified.
Disclosures. J. Nagel, Merck: Grant Investigator, Research grant 
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Background. Healthcare-associated pneumonia (HCAP) is a common and 
potentially life threatening illness. Pneumonia is one of the most common causes of 
healthcare associated infections. The purpose of our study was to investigate in a large 
multicenter cohort over a several year period, the association of specific organisms 
with patient mortality in HCAP patients.
Methods. This is a retrospective multicenter analysis of patients over 18  years 
of age hospitalized with HCAP over a 6-year period from 2008 to 2013 from 4 large 
healthcare institutions. Patients were identified by electronic medical record review. 
HCAP was defined by inclusion of patients with a discharge diagnosis of pneumonia by 
ICD-9 code plus associated antibiotic use in the initial 24 hours. Patients were consid-
ered to have HCAP if initial antimicrobial use included one of the following: cefepime, 
doripenem, meropenem, imipenem, or piperacillin-tazobactam, in combination with 
vancomycin or linezolid.
Results. There were 16084 patients. Staphylococcus aureus was the most common 
organism isolated in 368 patients and had 15.0% mortality at 30 days. Pseudomonas 
aeruginosa was isolated in 359 patients and had 24.2% mortality at 30  days. 
Acinetobacter baumannii was isolated in 200 patients, and accounted for 34.0% mor-
tality. Escherichia coli was isolated in 89 patients with 24.7% mortality. Klebsiella pneu-
moniae was isolated in 99 patients with 27.3% mortality. Commensal bacteria were 
isolated or positive cultures with no speciation occurred in 5214 of patients with 22.8% 







/ofid/article-abstract/4/suppl_1/S579/4296002 by guest on 19 O
ctober 2018
